About
Immunotherapy-based Diagnostics Platform
Protica Bio combines cutting-edge proteomics and machine learning to improve immunotherapy-based clinical decisions and new drug discoveries, with the goal of creating diagnostic capabilities and elevating the response rate for current and future treatments.
The company is utilizing a proprietary platform developed by a leading expert in the field of mass spectrometry from the Weizmann Institute. In addition to laboratory research, the company integrates deep proteomics with machine learning to create diagnostic capabilities and elevate the response rate for current and future treatments.
Identity
| Name | Protica Bio |
|---|---|
| Slug | protica-bio |
| Type / kind | startup |
| Source _id | wYNUtpX4un5HCDSQvxRfTsPO9AYyVZyRp12ru4Gr7DTzqm7LVPrIq5 |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | Jerusalem |
| HQ address | Sderot Wolfson 9, Jerusalem, Israel |
Web & social
| Website | https://www.protica.bio/ |
|---|---|
| https://www.linkedin.com/company/83010471 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTest Diagnostics & Screening
Technologies
Platforms & InterfacesWebArtificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesHealthcareLaboratories
Business models
B2C
Tags
immunotherapypharmaceuticalsmachine-learningcancer-diagnosticstreatmentsdrug-discovery
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}